TRAW Traws Pharma Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: TRAW

Price (delayed)

$0.67

Market cap

$14.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.9

Enterprise value

-$6.72M

onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has ...

Highlights
The EPS has grown by 7% from the previous quarter
Traws Pharma's net income has increased by 6% from the previous quarter
The equity has dropped by 62% year-on-year and by 26% since the previous quarter
The quick ratio has dropped by 53% year-on-year and by 13% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.onconova.com/
Peers: OMER OMGA

Key stats

What are the main financial stats of TRAW
Market
Shares outstanding
21.04M
Market cap
$14.1M
Enterprise value
-$6.72M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.32
Price to sales (P/S)
62.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-29.75
Earnings
Revenue
$226,000
EBIT
-$18.95M
EBITDA
-$18.93M
Free cash flow
-$17.95M
Per share
EPS
-$0.9
Free cash flow per share
-$0.86
Book value per share
$0.51
Revenue per share
$0.01
TBVPS
$1.08
Balance sheet
Total assets
$22.68M
Total liabilities
$12.01M
Debt
$0
Equity
$10.67M
Working capital
$13.44M
Liquidity
Debt to equity
0
Current ratio
2.46
Quick ratio
2.26
Net debt/EBITDA
1.1
Margins
EBITDA margin
-8,377%
Gross margin
100%
Net margin
-8,384.1%
Operating margin
-8,981.4%
Efficiency
Return on assets
-65.8%
Return on equity
-113.2%
Return on invested capital
N/A
Return on capital employed
-140.7%
Return on sales
-8,384.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TRAW stock price

How has the Traws Pharma stock price performed over time
Intraday
0%
1 week
-5.54%
1 month
-22.8%
1 year
-38.53%
YTD
-10.14%
QTD
-33.66%

Financial performance

How have Traws Pharma's revenue and profit performed over time
Revenue
$226,000
Gross profit
$226,000
Operating income
-$20.3M
Net income
-$18.95M
Gross margin
100%
Net margin
-8,384.1%
The net margin has grown by 6% from the previous quarter
Traws Pharma's operating margin has increased by 6% from the previous quarter but it has decreased by 3.4% YoY
Traws Pharma's net income has increased by 6% from the previous quarter
The company's operating income rose by 6% QoQ but it fell by 3.4% YoY

Growth

What is Traws Pharma's growth rate over time

Valuation

What is Traws Pharma stock price valuation
P/E
N/A
P/B
1.32
P/S
62.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-29.75
The EPS has grown by 7% from the previous quarter
The equity has dropped by 62% year-on-year and by 26% since the previous quarter
The stock's price to book (P/B) is 51% less than its 5-year quarterly average of 2.7 but 19% more than its last 4 quarters average of 1.1
The price to sales (P/S) is 68% lower than the 5-year quarterly average of 195.4 and 21% lower than the last 4 quarters average of 78.2

Efficiency

How efficient is Traws Pharma business performance
TRAW's return on equity has dropped by 112% year-on-year and by 19% since the previous quarter
TRAW's return on assets has dropped by 59% year-on-year and by 8% since the previous quarter
The ROS has grown by 6% from the previous quarter

Dividends

What is TRAW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TRAW.

Financial health

How did Traws Pharma financials performed over time
TRAW's total assets is 89% greater than its total liabilities
The quick ratio has dropped by 53% year-on-year and by 13% since the previous quarter
The current ratio has contracted by 50% YoY and by 12% from the previous quarter
The debt is 100% less than the equity
The equity has dropped by 62% year-on-year and by 26% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.